title: Polyribonucleotides induce nitric oxide production by human monocyte-derived macrophages.
abstract: Cytokine-mediated activation of inducible nitric oxide synthase (iNOS) in monocytes or macrophages is species specific. In contrast to rat or mouse, human macrophages do not produce measurable levels of nitric oxide (NO) when induced by inflammatory mediators. Exposure to noncytokine mediators such as tumor cells or viruses, however, has recently been shown to activate human iNOS. NO production in response to these mediators is much lower than that seen for rat or mouse cells and often requires several days of stimulation. We have found that the synthetic, doublestranded polyribonucleotide polyinosinic-polycytidilic acid (Poly I:C), commonly used to mimic viral exposure, activated iNOS in human monocyte-derived macrophages (MDM). The production of NO, measured by nitrite accumulation, was detected after 24 h of stimulation with Poly I:C. The single-stranded polyribonucleotide Poly I, but not Poly C, also increased NO production. Nitrite production was enhanced when the MDM were primed (pretreated) with gamma or alpha interferon or other immune mediators such as IL-4 and was reduced by the iNOS inhibitor, N-methyl-L-arginine (L-NMMA). The use of Poly I:C to initiate NO production in human macrophages provides a useful tool to study the differences between the commonly used animal models and human cells and may provide insight into the pathophysiological significance of these differences.
authors.affiliation: Department of Physiology and Biophysics, Georgetown University Medical Center, Washington, DC 20007, USA.
authors.forename: J C
authors.initials: JC
authors.lastname: Snell
authors.forename: O
authors.initials: O
authors.lastname: Chernyshev
authors.forename: D L
authors.initials: DL
authors.lastname: Gilbert
authors.forename: C A
authors.initials: CA
authors.lastname: Colton
mesh_terms: D002478:Cells, Cultured; D004790:Enzyme Induction / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000494:pharmacology; D016899:Interferon-beta / Q000494:pharmacology; D007371:Interferon-gamma / Q000494:pharmacology; D015847:Interleukin-4 / Q000494:pharmacology; D008264:Macrophages / Q000378:metabolism*; D009569:Nitric Oxide / Q000096:biosynthesis*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D011066:Poly C / Q000494:pharmacology; D011069:Poly I / Q000494:pharmacology; D011070:Poly I-C / Q000494:pharmacology*; D011994:Recombinant Proteins; D019323:omega-N-Methylarginine / Q000494:pharmacology
chemical_list: D004791:Enzyme Inhibitors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D015847:Interleukin-4; D011069:Poly I; D019323:omega-N-Methylarginine; D011066:Poly C; D009569:Nitric Oxide; D016899:Interferon-beta; D007371:Interferon-gamma; D019001:Nitric Oxide Synthase; D011070:Poly I-C